Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Clene Inc (CLNN)
NASDAQConsumer StaplesBiotechnologySnapshot 2026-11-04
$3.97-3.17%
Close 2026-11-05 · 1-day change
NASDAQConsumer StaplesBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CLNN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Submit NDA for CNM-Au8 in Q3 2026 | Clene plans to submit a New Drug Application for CNM-Au8 in Q3 2026. | Improving | NDA submission delayed beyond Q3 2026 | NDA status: Not yet submitted (Target: Q3 2026) Q3 2026 earnings released; August survival data supports NDA; no explicit NDA submission confirmation in evidence. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Third Quarter 2026 and Recent Operating Highlights CNM-Au8 for the treatment of ALS In October, Clene submitted an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS.” ““Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS,” said Rob Etherington, President and CEO of Clene.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, not a durable earnings compounder: it has minimal revenue and continues to report operating losses. The long-term thesis is on watch, with an NDA submission reported in October but limited evidence of commercial progress.
Valuation evidence is neutral, so the snapshot does not show that CLNN is clearly cheap or expensive versus peers. The expectations gap is hard to assess from the supplied evidence, though weak recent results and an August earnings miss point to limited near-term confidence.
Near term, financial performance is likely to remain weak: quarterly revenue was very small relative to operating losses, and the risk of another earnings miss is elevated. The NDA submission is a meaningful regulatory step, while cash raised through the September offering was expected to fund operations through mid-first quarter 2027; that runway depends on available resources.
The multi-year thesis depends on regulatory progress for CNM-Au8 and whether preparations for the confirmatory Phase 3 RESTORE-ALS study advance to a trial-start or enrollment milestone. Near-term confidence also hinges on whether the company avoids a guidance cut and extends its operating runway without relying on uncertain funding.
For the next 1 to 3 years, CLNN remains a high-risk watch thesis: regulatory progress is tangible, but weak finances, limited runway, and volatile management execution leave major uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage cash flow and operating expenses | Net loss decreased from $9.2M in 2025-Q4 to $8.1M in 2026-Q1, showing some expense control progress. | Intact | Net loss increases above $9.2M or fails to improve over next 4 quarters | Net income: $3.915M FY2026-Q3; GAAP. Published target: Net loss <= $8.1M in Q1 2026 and trend downward. Target period is not explicitly aligned with this observation. Nov 4, 20263,915,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Extend operating runway into Q4 2026 | The company has extended its operating runway into Q4 2026. | Improving | Operating runway falls short of Q4 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.47 → $-1.50 · observed estimates
$0.02B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-25 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-26 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-27 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-28 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-29 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-30 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-07-31 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-01 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-02 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-03 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-04 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-05 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-06 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-07 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-08 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-09 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-10 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-11 | $-1.79 | $23,644,200 | 2 / 5 |
| 2026-08-12 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-13 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-14 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-15 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-16 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-17 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-18 | $-1.47 | $23,644,200 | 3 / 3 |
| 2026-08-19 | $-1.47 | $23,644,200 | 3 / 4 |
| 2026-08-20 | $-1.50 | $23,269,600 | 3 / 4 |
| 2026-08-21 | $-1.50 | $23,269,600 | 3 / 4 |
| 2026-08-22 | $-1.50 | $23,269,600 | 3 / 4 |
| 2026-08-23 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-24 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-25 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-26 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-27 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-28 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-29 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-30 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-08-31 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-01 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-02 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-03 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-04 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-05 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-06 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-07 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-08 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-09 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-10 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-11 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-12 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-13 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-14 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-15 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-16 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-17 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-18 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-19 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-20 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-21 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-22 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-23 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-24 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-25 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-26 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-27 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-28 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-29 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-09-30 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-01 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-02 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-03 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-04 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-05 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-06 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-07 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-08 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-09 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-10 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-11 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-12 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-13 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-14 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-15 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-16 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-17 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-18 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-19 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-20 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-21 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-22 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-23 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-24 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-25 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-26 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-27 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-28 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-29 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-30 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-10-31 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-11-01 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-11-02 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-11-03 | $-1.50 | $26,400,000 | 3 / 4 |
| 2026-11-04 | $-1.50 | $26,400,000 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.